Yinhua CSI Innovative Drugs Industry ETF (159992) Rises 1.91%, with Share Count Growing by 496 Million Units Over the Past 2 Weeks

NewTimeSpace (newtimespace.com) News, – As of 13:38 on July 29, 2026, Yinhua Innovative Drug ETF (159992) rose 1.91%, with its latest price at RMB 0.86. Over a longer horizon, as of July 28, 2026, the ETF had accumulated a gain of 11.42% over the past month.

In terms of liquidity, Yinhua Innovative Drug ETF recorded a turnover rate of 3.93% during the session, with trading volume reaching RMB 678 million. Over a longer period, as of July 28, the ETF’s average daily turnover over the past month was RMB 1.486 billion, ranking first among comparable funds.

In terms of scale, the ETF’s scale grew by RMB 1.162 billion over the past month, achieving significant growth and ranking 3rd among 7 comparable funds in new scale additions. (Data source: Wind)

In terms of units, the ETF’s share count grew by 496 million units over the past 2 weeks, achieving significant growth and ranking 3rd among 7 comparable funds in new share additions. (Data source: Wind)

On capital inflows, the latest net capital inflow for Yinhua Innovative Drug ETF was RMB 60.2782 million. Over a longer horizon, the ETF saw net inflows on 13 out of the past 20 trading days, with total net inflow of RMB 292 million, averaging RMB 14.6020 million per day. (Data source: Wind)

Data shows that leveraged funds are continuing to position themselves. Yinhua Innovative Drug ETF recorded a net financing purchase of RMB 3.2345 million month‑to‑date, with its latest margin balance standing at RMB 703 million. (Data source: Wind)

As of July 28, the net value of Yinhua Innovative Drug ETF had risen 37.10% over the past 2 years. In terms of return capability, as of July 28, 2026, since its inception, the ETF achieved a highest single‑month return of 22.79%, a longest consecutive winning streak of 4 months with a cumulative gain of 53.27%, and an average monthly return of 6.43% during up months. As of July 28, 2026, the ETF’s 3‑month excess annualized return over its benchmark was 4.42%.

In terms of drawdown, as of July 28, 2026, the ETF’s half‑year drawdown relative to its benchmark was 0.18%. The recovery period after drawdown was 28 days, the fastest recovery among comparable funds.

On fees, Yinhua Innovative Drug ETF charges a management fee of 0.50% and a custody fee of 0.05%.

On tracking accuracy, as of July 28, 2026, the ETF’s 1‑year tracking error was 0.033%, representing a relatively high tracking precision among comparable funds.

Yinhua Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The index selects no more than 50 representative listed company securities whose primary business involves innovative drug research and development as index samples, reflecting the overall performance of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.